Curated News
By: NewsRamp Editorial Staff
November 05, 2026
Annovis Bio Launches Public Offering to Fund Buntanetap Trials
TLDR
- Annovis Bio's proposed offering could fund Phase 3 trials for buntanetap, potentially giving ANVS a competitive edge in neurodegenerative disease treatments.
- Annovis Bio will issue common stock or pre-funded warrants with accompanying warrants, using net proceeds to advance buntanetap's clinical development for Alzheimer's and Parkinson's.
- Annovis Bio's offering aims to advance buntanetap, a potential oral therapy that could halt disease progression and improve cognitive and motor functions for patients.
- Buntanetap is an investigational oral therapy that inhibits translation of multiple neurotoxic proteins, including APP, tau, and alpha-synuclein, through a specific RNA-targeting mechanism.
Impact - Why it Matters
This capital raise is critical for Annovis Bio as it seeks to advance buntanetap, a novel oral therapy targeting the underlying causes of Alzheimer’s and Parkinson’s diseases, through Phase 3 clinical trials. If successful, buntanetap could offer a disease-modifying treatment for these devastating neurodegenerative conditions, addressing a significant unmet medical need. The offering provides the necessary funding to continue this important research, potentially bringing hope to millions of patients and their families. Moreover, it underscores the challenges of financing late-stage biotech development and the importance of investor support in bringing innovative therapies to market.
Summary
Annovis Bio, Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company based in Malvern, Pennsylvania, has announced a proposed underwritten public offering of common stock or pre-funded warrants in lieu of common stock, together with accompanying warrants to purchase common stock. The securities will be issued separately but must be purchased together, with Canaccord Genuity acting as sole bookrunner. The company intends to use the net proceeds to advance clinical development of its investigational oral therapy buntanetap for Alzheimer’s disease and Parkinson’s disease, as well as for working capital and general corporate purposes. The offering remains subject to market and other conditions, and there is no assurance regarding its completion, size, or terms.
Annovis Bio is focused on developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
The announcement was disseminated through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, visit https://www.InvestorWire.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Annovis Bio Launches Public Offering to Fund Buntanetap Trials
